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ABSTRACT
Hypomethylation of DNA is a hallmark of cancer and its analysis as tumor 
biomarker has been proposed, but its determination in clinical settings is hampered 
by lack of standardized methodologies. Here, we present QUAlu (Quantification of 
Unmethylated Alu), a new technique to estimate the Percentage of UnMethylated Alu 
(PUMA) as a surrogate for global hypomethylation.
QUAlu consists in the measurement by qPCR of Alu repeats after digestion of 
genomic DNA with isoschizomers with differential sensitivity to DNA methylation. 
QUAlu performance has been evaluated for reproducibility, trueness and specificity, 
and validated by deep sequencing. As a proof of use, QUAlu has been applied to a 
broad variety of pathological examination specimens covering five cancer types.
Major findings of the preliminary application of QUAlu to clinical samples include: 
(1) all normal tissues displayed similar PUMA; (2) tumors showed variable PUMA with 
the highest levels in lung and colon and the lowest in thyroid cancer; (3) stools from 
colon cancer patients presented higher PUMA than those from control individuals; (4) 
lung squamous cell carcinomas showed higher PUMA than lung adenocarcinomas, and 
an increasing hypomethylation trend associated with smoking habits. 
In conclusion, QUAlu is a simple and robust method to determine Alu 
hypomethylation in human biospecimens and may be easily implemented in research 
and clinical settings.
INTRODUCTION
Extensive evidence describes cancer as a 
combination of genetic and epigenetic alterations which 
cooperate at every step of the tumor progression (reviewed 
in [1]). DNA methylation is the most well-characterized 
epigenetic mark in mammals and consists in the covalent 
addition of a methyl group to the cytosine located 
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within the CpG dinucleotide. It is frequently associated 
with silenced chromatin and transcriptional repression 
(reviewed in [2-3]). Among all the epigenetic alterations 
that delineate cancer genomes, loss of global DNA 
methylation has been considered a hallmark. Numerous 
works have demonstrated that DNA hypomethylation is 
an early and sustained event in tumorigenesis. Besides, it 
promotes a permissive landscape for cancer development 
and progression by encouraging chromosomal instability, 
imprinting loss, aberrant gene expression and transposon 
activation (reviewed in [2-3]). More importantly, it has 
been reported a strong association between the degree 
of DNA hypomethylation and the tumor grade and stage, 
which has attracted great interest for its potential clinical 
value, not only in cancer diagnosis and prognosis [4-9], 
but also as a marker of cancer risk [9-12].
A wide variety of techniques have been designed 
to measure global DNA methylation, some of which 
quantify the overall levels of 5-methylcytosine in the 
genome compared with unmethylated cytosines (e.g. 
HPLC, immunochemical assay, etc.), while others assess 
the methylation levels of specific genome compartments 
(reviewed in [9, 13]). Among the second group, the most 
widely used methods are those based on repeat elements, 
as they exhibit a high copy number and are widespread 
throughout the human genome. Nevertheless, none of 
them has been established in the clinical practice due 
in part to technical, economical and time shortcomings, 
which preclude a standardized alternative.
Here we present a new method, Quantification of 
Unmethylated Alu (QUAlu), which uses Alu repeats 
as surrogate reporter of global DNA methylation. Alu 
repeats are primate-specific transposable elements that 
belong to the Short Interspersed Elements (SINEs) 
family and represent the most abundant class of repetitive 
sequences in the human genome (1.1 million copies per 
haploid genome) [14]. Alu elements contain up to 25% 
of the overall CpG sites in the genome (Table 1) and are 
highly methylated in somatic tissues. Interestingly, they 
are located in gene-rich regions [15].
QUAlu is a simple and rapid method based on the 
digestion of genomic DNA with the methylation-sensitive 
and insensitive isoschizomers HpaII/MspI, the ligation 
of an adaptor and a qPCR using primers specific for the 
Alu consensus sequence. We have applied this technique 
to a broad variety of pathological examination samples 
including fresh frozen tissues, formalin-fixed paraffin-
embedded (FFPE) sections, fine-needle aspiration biopsies 
(FNAB), stools and liquid biopsies. Our preliminary 
results underscore the potential clinical utility of the 
assessment of unmethylated Alu elements by QUAlu.
RESULTS
QUAlu design and technical evaluation
According to the reference human assembly hg19, 
there are over 28 millions of CpG dinucleotides in the 
human genome and more than half are located within 
repeat elements, being Alu elements those containing 
the highest fraction, namely 25.4% (Table 1). Therefore, 
we selected Alu elements as the most adequate surrogate 
reporter of global methylation and developed QUAlu 
technique, a method to identify unmethylated Alu repeats 
which shares the quantitative nature of the related 
technique LUMA [16] and the specificity of QUMA [17]. 
Fundamentals of QUAlu assay are outlined in Figure 1 and 
Supplementary Figure S1. QUAlu is based on the different 
methylation sensitivity of the isoschizomers HpaII/MspI 
(see Materials and Methods and Supplementary Material), 
whose recognition site is C/CGG, located in the Alu 
consensus sequence AACCCGG present in 14.4% of Alu 
elements (Table 1). Noteworthy, analysis of whole genome 
bisulfite sequencing data [18] showed that the HpaII/MspI 
sites embedded in CpG islands may be used as reporters of 
the overall methylation of these genomic elements [19]. In 
this regard, we also confirmed that this postulate may be 
also applied to Alu repeats: more than 90% of the HpaII/
MspI sites within the Alu consensus sequence AACCCGG 
showed concordant methylation levels with the whole 
Alu sequence (Supplementary Table S4). To determine 
the virtual representativeness of QUAlu (QUAluome), 
an electronic qPCR simulation was performed showing 
a theoretical coverage of 155 878 Alu elements (see 
Supplementary Material), which corresponded to the 
13.65% of the Aluome, with a bias toward amplification 
of young subfamilies (Supplementary Figure S2).
To assess the linearity of QUAlu, different starting 
amounts of HCT116 genomic DNA, ranging from 0.3 to 
80 ng, were used. As it can be observed in Figure 2A, all 
quantifications showed excellent linearity (R2> 0.98 in all 
cases). Moreover, similar percentages of unmethylated Alu 
elements were obtained, being the overall average 8.8± 2.2 
(Supplementary Figure S3A). The same assay was done 
with clinical samples from normal tissues of lung, colon 
and thyroid, obtaining an excellent linearity in all cases 
(Supplementary Table S5). 
The inter-assay repeatability was assessed by 
analyzing the same HCT116 genomic DNA in 39 
independent QUAlu assays. The mean of all the analyses 
was 9.9% and the standard deviation ±1.6. Furthermore, 
replicates of tumor and normal clinical samples were 
measured in different plates confirming that the technique 
is reproducible (R2 = 0.981) (Figure 2B). Importantly, 
the feasibility of QUAlu in samples containing partially 
degraded DNA was verified (Supplementary Material and 
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Figure 1: QUAlu technique diagram. Genomic DNA is digested using HpaII and MspI isoschizomers (DNA methylation sensitive 
and insensitive, respectively), ligated to a synthetic adaptor, and Alu elements are specifically amplified by qPCR in two separated reactions. 
The ratio between the two reactions gives the percentage of unmethylated Alu elements (PUMA). DNA normalization is performed by 
parallel amplification of L1PA.
Figure 2: Evaluation of QUAlu technique. A. Standard curves showing the linear range of the different qPCRs performed in a 
QUAlu assay. HCT116 genomic DNA amounts ranging from 0.3 to 80 ng were used. B. Correlation of the percentage of unmethylated Alu 
elements (PUMA) determined by QUAlu in two independent experiments. 
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Supplementary Figure S3B-S3C).
It is of note that consistent QUAlu results may be 
achieved with DNA amounts well below one haploid 
genome. In fact, linear range response was reached with 
as little as 0.005 pg of DNA per PCR tube (equivalent 
to 0.002 haploid genomes) (Supplementary Figure S4). 
The low requirements of QUAlu are due to the multiplex 
nature of its target (a large pool of more than one hundred 
thousand Alu repeats), reaching sensitivity detection 4 
to 5 orders of magnitude higher than a single copy locus 
(e.g. promoter region of Digestive organ expansion factor 
homolog (zebrafish) -DIEXF- gene) (Supplementary 
Figure S4 and Supplementary Material). Noteworthy, the 
complexity of the QUAlu product is visualized as a broad 
melting peak for both the HpaII and the MspI samples, 
contrasting with the narrower peak of a single PCR 
product (Supplementary Figure S5). 
Finally, the specificity of QUAlu to amplify Alu 
elements was validated by next-generation sequencing 
of five QUAlu determinations. The results showed 
that 97% of the reads (range 96.6-98.1%) obtained 
from the sequenced samples aligned with Alu repeats 
(Supplementary Table S6) and confirmed the complex 
composition of QUAlu product composed of multiple 
different Alu elements with similar distributions among 
all the analyzed samples (Supplementary Figure S6).
QUAlu application to fresh frozen human cancer 
samples
QUAlu technique was applied to analyze the levels 
of unmethylated Alu elements in different cancer types 
and their normal counterparts (Table 2 and Supplementary 
Table S7). Interestingly, the different normal tissue types 
showed similar values of Percentage of UnMethylated 
Alu elements (PUMA) (Table 2) (Kruskal Wallis test, 
p-value = 0.308), being the average PUMA 6.0 ± 2.1 
(range 1.8-14.8). However, PUMA showed a broad 
variation in tumors, ranging from 0.9 to 40.5 (average 
= 10.7 ± 6.8). Furthermore, important differences were 
observed between cancer types (Table 2 and Figure 3A) 
(Kruskal Wallis test, p-value < 0.05), with colon and lung 
exhibiting 2-3 fold higher levels of unmethylated Alu 
repeats as compared with thyroid, prostate and breast 
cancer (Supplementary Tables S7 and S8). 
The comparison between normal and tumor samples 
showed statistically significant differences in most cancer 
types, except in prostate cancer (Mann-Whitney U test, 
p-value = 0.357) (Figure 3A and Table 2).
Since there were no differences among normal 
tissues in the proportion of unmethylated Alu elements, 
the 99th percentile (PUMA = 12%) was taken as a cut-
off value to consider a tumor as hypomethylated. Thus, 
particular analysis of each tumor type revealed that 62.5% 
of colon and 64.1% of lung tumors were hypomethylated, 
while in breast and prostate tumors this figure was 20% 
Table 1: Alu repeat content in the human genome and representativeness in the virtual QUAlu a
Sequence No of elements Base pairs No of CpGs No of HpaII/MspI sites AACCCGG hitsd QUAluomed
Alu b 1,194,734 305,076,148(9.7%)
7,173,987
(25.4%)
742,725
(32.3%)
172,574
(79.1%) 155,878
LINE c 1,498,690 638,481,131(20.4%)
3,412,416
(12.1%)
155,813
(6.8%)
6,881
(3.2%) 0
CpG 
islands 28,691
21,842,742
(0,7%)
2,089,537
(7.4%)
270,622
(11.8%)
4,470
(2.1%) 0
Genome - ~3,200,000,000(100%)
28,217,009
(100%)
2,297,221
(100%)
218,131
(100%) 0
aData based on GRCh37/hg19 human genome assembly.
bRepeatMasker’s Alu repFamily members discarding FLAMs and FRAMs.
cRepeatMasker’s LINE repClass members.
dVirtual QUAlu amplicons.
Table 2: Percentage of Unmethylated Alu repeats (PUMA) in different human tissues and tumors
Thyroid Prostate Breast Colon Lung
Normal tissue 6.2 ± 1.6(n = 9)
4.8 ± 2.6
(n=7)
5.6 ± 2.66 
(n=14)
6.9 ± 1.9 
(n=16)
5.9 ± 2.0
 (n=37)
Tumor tissue 8.2 ± 3.1 (n=59)
8.5 ± 8.8
 (n=18)
10.0 ± 5.9 
(n=20)
14.6 ± 5.2 
(n=16)
14.6 ± 8.3
 (n=39)
p-value a 0.032 0.357 0.002 < 0.001 < 0.001
aNormal vs. Tumor, Mann-Whitney U test
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and 16.7%, respectively. Otherwise, only 11.9% of thyroid 
tumors had percentages of unmethylated Alu elements 
above the reference value (Supplementary Figure S7). 
When considering only the matched normal-tumor pairs 
of all cancer types (n = 81), the difference among them 
was evident in most cases (paired Mann-Whitney U test 
p-value<0.001). About one third of colon (5/16) and 
lung (13/37) tumors displayed a high hypomethylation 
as compared with the paired normal tissue (fold change 
greater than 3). Contrarily, this big difference was 
uncommon in breast (2/14), prostate (1/7) or thyroid (0/7) 
cancer (Supplementary Tables S7 and S9).
Evaluation of PUMA as biomarker in specific 
cancers
To estimate the potential value of the percentage 
of unmethylated Alu elements to discriminate between 
normal and tumoral tissue we performed ROC analyses 
(Figure 3B). Area Under the Curve (AUC) values 
confirmed that PUMA was a good biomarker (AUC > 
0.8) for breast, colon and lung cancer, with sensitivities 
and specificities >80%, except for breast cancer, whose 
sensitivity reached 92.9% but the specificity was lower 
Figure 3: Comparison and diagnostic value of QUAlu among different cancer types. A. PUMA in different cancer types 
(normal tissue (N) and tumor (T)); the median of each group is represented by a black line. B. Receiver Operating Characteristic curves 
for the diagnosis of lung, colon, breast, thyroid and prostate cancer according to the percentage of unmethylated Alu (PUMA) elements 
determined by QUAlu. 
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(60%). Otherwise, for both prostate and thyroid cancer, 
although the sensitivity reached 100%, the specificity was 
low (44.4% and 27.3%, respectively). The cut-off values 
varied from tissue to tissue (Figure 3B), with the lowest 
levels in lung (6.97) and the highest in thyroid (9.54).
Moreover, to evaluate the clinical value of the 
QUAlu assay, we performed additional statistical analyses 
in two cancer types with the highest and the lowest 
PUMA, namely lung and thyroid cancer. 
As described above, lung cancers exhibited high 
levels of hypomethylated Alu elements, but differences 
were also detected among lung cancer subtypes. 
Specifically, lung squamous cell carcinoma showed 
the highest PUMA (16.8 ± 8.8) compared with lung 
adenocarcinomas (12.2 ± 6.1) (Mann-Whitney U test 
p-value = 0.001) (Figure 4A and Supplementary Table 
S10). On the other hand, while no significant differences 
were observed in PUMA among lung normal tissue from 
never smokers, former smokers (more than 10 years) 
and current smokers (Kruskal Wallis test p-value >0.05), 
there was a significant increasing trend (Mann-Whitney 
U test, p-value = 0.006) of lung tumors to become more 
unmethylated in current smokers compared to former 
smokers (Figure 4B). 
As regard to thyroid cancer, there were no 
significant differences in the percentage of unmethylated 
Alu elements in relation to histology subtype (Kruskal 
Wallis test, p-value = 0.231) or genetic alteration (RAS or 
BRAF mutations) (Kruskal Wallis test p-value = 0.147). 
Figure 4: Comparison of QUAlu among different clinical characteristics and sample types. A. PUMA in normal lung 
tissue, lung adenocarcinoma (LAD) and lung squamous cell carcinoma (LSCC) and B. in lung cancer patients according to their smoking 
habits. C. PUMA in different sample types: FFPE (colon cancer patients), stool (healthy donors and colon cancer patients), liquid biopsy 
(plasma from healthy donors, and plasma and serum from lung cancer patients), FNAB (thyroid goiter patients), fresh tissue (thyroid cancer 
patients). The median of each group is represented by a black line. Normal (N), tumor (T), healthy donors (H), plasma (P), serum (S), no 
detectable samples (ND).
Oncotarget10542www.impactjournals.com/oncotarget
QUAlu application to diverse pathological 
examination biospecimens
Next, we evaluated the applicability of QUAlu to 
biospecimens obtained in standard pathological procedures 
often containing low amount of poor quality DNA (FFPE, 
FNAB, liquid biopsies and stools). Due to the low amount 
of starting material, DNA was not quantified and 1 ul of 
the extracted DNA was used for QUAlu analysis (see 
Supplementary Material). All samples produced detectable 
levels of amplified Alu elements (qAlu M Cq range: 16 to 
30, qAlu H Cq range: 19 to 34) (Supplementary Figure 
S8), with the exception of plasma samples obtained from 
healthy individuals and one stool sample from one colon 
cancer patient.
The low number of samples precluded a robust 
comparison of the results, but some insightful trends were 
observed (Figure 4C). FFPE colon tumors showed higher 
PUMA than the matching normal samples (paired Mann-
Whitney U test p-value = 0.062). Moreover, elevated Alu 
hypomethylation in the stools was more frequent in colon 
cancer patients than in control individuals (Mann-Whitney 
U test p-value = 0.079). Interestingly, liquid biopsies 
produced similar PUMA in plasma and serum from 
lung cancer patients, but did not amplify in cancer-free 
controls, which is consistent with the common absence of 
circulating free DNA in healthy individuals [20].
Finally thyroid goiters FNABs showed a PUMA in 
the same range than normal tissues with some exceptions: 
four cases presented a PUMA above 8.8, the highest value 
in normal thyroid tissue (Figure 4C). 
DISCUSSION
Most of human genome is methylated, but in a 
wide range of pathologies, including cancer, a global 
DNA hypomethylation occurs affecting in large extent 
repetitive elements, which constitute ~45% of the genome. 
Weisenberger et al. [21] demonstrated that the methylation 
of different repetitive sequences, namely, LINE-1, Alu 
and satellite 2 (Sat2), significantly correlated with global 
methylation levels measured by high performance liquid 
chromatography (HPLC), and proposed the use of these 
repeats as surrogate reporters of global methylation. 
LINEs have been broadly used to estimate the global 
levels of hypomethylation [22-24], but Alu elements 
display some features that make them more suited for 
this purpose. Namely, Alu repeats constitute the most 
abundant retrotransposon and contain 25% of all the CpGs 
in the human genome. Moreover, due to their prevalent 
localization in gene-rich regions [15] epigenetic variations 
in Alu repeats may have direct implications in gene 
regulation, and by extension, in tumor biology. 
Here we present QUAlu, a new technique to 
measure the levels of DNA unmethylation in Alu repeats, 
with several features that facilitate a direct implementation 
in clinical and research settings. These include a 100 fold 
higher sensitivity than other related methods [25], as 
accurate determinations can be performed with as little 
as 300 pg of DNA (corresponding to approximately 150 
diploid cells). QUAlu specificity for Alu elements is 
extremely high, as demonstrated by deep sequencing of its 
products, where 97% of the reads mapped in Alu repeats. 
Moreover, thanks to the calibration with internal 
controls (L1PA simultaneously with Alu repeats), QUAlu 
is relatively unaffected by the quantity and quality 
of the starting material in artificially degraded DNA. 
Furthermore, we have demonstrated that this technique is 
amenable to be applied to a broad spectrum of pathological 
examination specimens routinely collected in clinical 
settings (frozen tissues, FFPE, liquid biopsies, stools and 
FNAB). In spite of the low number of samples analyzed, 
preliminary results are promising, especially for FFPE 
and stools. Nevertheless, direct applicability of QUAlu 
in different clinical settings requires the analysis of large 
series of cases to define the threshold, sensitivities and 
specificities.
With clinical practice in mind, technical benefits 
of QUAlu include the small number of steps (digestion-
ligation, real time PCR and analysis), the short time 
required to complete the determination (less than 5 hours 
from the DNA to the final result, even without automation 
of the process), and the low cost (about 6.3 US$ per 
sample, including technician labor). 
As mentioned above, several techniques have been 
developed to estimate global methylation, and many 
of them target repeat elements as surrogate reporters 
(reviewed in [9, 13]). While most of these methods may 
constitute good alternatives to compare global methylation 
levels among a few samples, their implementation as a 
clinical tool is not a straightforward approach due to either 
technical complexity or exquisite sample necessities. 
QUAlu simplicity and limited equipment requirements 
facilitate its implementation in most laboratories.
To assess the clinical potential of QUAlu, we 
determined the extent of Alu hypomethylation in different 
human cancers by analyzing normal and tumor tissues. 
In a first analysis we compared the different normal 
tissues and different individuals, showing that the levels 
of unmethylated Alu elements were very consistent from 
tissue to tissue and from individual to individual. This 
result was in agreement with previous studies analyzing 
global DNA methylation by MethyLight and HPLC [21] or 
targeting Alu elements [26-27], but not with other works 
reporting tissue-associated global methylation differences 
targeting LINE-1 [28].
Our data suggests that the degree of 
hypomethylation is variable among different cancer 
types, with thyroid, prostate and breast cancer exhibiting 
low levels of hypomethylation, while cancers of colon 
and lung displayed the highest levels. Chalitchagorn et al. 
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[28] analyzed LINE-1 methylation using bisulfite based 
PCR in several cancers, and although they found high 
levels of hypermethylation in some types (e.g. esophagus 
cancer), no hypomethylation was observed among the 
ones analyzed in our study. This might be explained by 
the low sensitivity of their technique or the low number of 
samples analyzed.
It is interesting to note that the low-hypomethylation 
cancer group included hormone-related tissues (thyroid, 
prostate and breast) with no direct interaction with 
external factors, while the high-hypomethylation group 
(colon and lung) was composed by tumors with a high 
exposure to environmental factors (e.g. diet, air). While 
we do not know the reason for this association, there are 
evidences supporting the impact of certain environmental 
factors (drugs, chemicals, pollutants and other agents) 
in the deregulation of epigenetic enzymes, which will 
eventually generate epigenetic changes, including DNA 
hypomethylation, that may accumulate over the time 
causing alterations in key cellular processes and promoting 
cancer [29-30]. Noteworthy, it has been reported that Alu 
hypomethylation (but not LINE-1 hypomethylation) in 
esophageal mucosa may reflect an epigenetic field for 
cancerization in esophageal carcinogenesis [12]. Other 
alternative explanations may be related with the dynamics 
of tumor progression in different tumor types and the role 
of DNA hypomethylation behind specific deregulation of 
biological pathways, including genomic stability [31-32].
Confirming previous reports [33] we found 
significant differences in the levels of hypomethylation 
among the two types of lung cancers considered here. 
Lung adenocarcinomas, the histological subtype most 
frequently associated with never-smokers and former 
smokers, were less hypomethylated than lung squamous 
cell carcinomas. Many studies have suggested a strong 
correlation between loss of DNA methylation and smoking 
habit in cancer patients [34-36], but also in healthy people 
[37-38]. In this regard, we found a significant increase 
of hypomethylation in current smokers compared to 
former smokers, but this trend was not observed in the 
adjacent normal tissue. This result may indicate different 
mechanisms of tumor progression in ex-smokers as 
compared with current smokers.
In summary, we have demonstrated that QUAlu is 
a feasible approach to analyze global DNA methylation 
in almost any type of biospecimen routinely collected 
in ordinary clinical settings. DNA hypomethylation is 
a hallmark of cancer but, as we have shown, its degree 
is highly variable. Its determination with a technique 
as QUAlu may have a broad spectrum of applications 
including diagnostic and prognostic evaluations.
MATERIALS AND METHODS
Samples
This study included a total of 300 pathological 
examination samples of different sources: 220 fresh 
frozen tissue samples (Supplementary Tables S1and S2), 
10 FFPE samples, 31 liquid biopsies, 19 stool samples 
and 20 thyroid goiter FNAB samples. Regarding fresh 
frozen tissues, 16 colorectal carcinomas and their paired 
normal adjacent tissues were obtained from Hospital 
Universitari de Bellvitge (Barcelona, Spain). Forty-four 
thyroid carcinomas and 9 paired adjacent thyroid tissues 
were obtained as described in our previous study [39]. 
DNA of 20 breast carcinomas and 14 paired normal 
adjacent tissues, 18 prostate carcinomas and 7 paired 
normal adjacent tissues, and 39 lung carcinomas and 37 
normal adjacent tissues were obtained from the Spanish 
National DNA Bank (BNADN, Salamanca, Spain). Patient 
characteristics are shown in Supplementary Tables S1 and 
S2. Five normal and tumoral paired colorectal carcinoma 
FFPE samples were obtained from Cooperative Human 
Tissue Network (CHTN). Nine stool samples from 
colorectal carcinoma patients and 10 from healthy donors 
were obtained from Hospital Universitari de Bellvitge 
(Barcelona, Spain). Finally, nine plasma and serum paired 
lung carcinoma liquid biopsies, 13 plasma liquid biopsies 
from healthy donors and 20 thyroid goiter FNAB samples 
were obtained from Hospital Universitari Germans Trias 
i Pujol (Badalona, Spain). The study was approved by 
the Hospital Germans Trias i Pujol Ethics Committee. 
Informed consent was obtained before surgery.
The colorectal carcinoma cell line HCT116 was 
obtained from the American Type Culture Collection 
(ATCC) and was authenticated on 3rd March 2014 by using 
the AmpFLSTR® Identifiler® Plus PCR Amplification Kit 
(Applied Biosystems). Cells were cultured in D-MEM/
F12, supplemented with sodium pyruvate, L-glutamine 
and 10% fetal bovine serum (Life Technologies, MD, 
USA) and were maintained at 37ºC in a 5% CO2 
atmosphere. Genomic DNA was isolated using different 
methods as described in the Supplementary Material.
Human genome sequence data sets
We used the GRCh37/hg19 human genome 
assembly. Genomic positions of Alu elements, LINE 
sequences, CpG islands and CpG dinucleotides were 
retrieved from the UCSC MySQL repository (genome-
mysql.cse.ucsc.edu). Motif search was performed with 
EMBOSS (http://emboss.sourceforge.net/). To count the 
number of overlapping features (Table 1) we used the 
BEDTools package (v2.19.1, [40]). For more technical 
details see Supplementary Material.
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Quantification of Unmethylated Alu (QUAlu) 
assay 
The principle underlying this technique is the 
selective amplification of Alu repeats containing an 
unmethylated CpG site within the consensus sequence 
AACCCGG. Briefly, genomic DNA was digested in 
parallel in two separated tubes with HpaII and MspI 
methylation-sensitive and -insensitive isoschizomers, 
respectively, which leave identical sticky ends (C/CGG). 
Next, a synthetic adaptor was ligated to the digested 
DNA fragments. Quantification was performed by qPCR 
using a primer complementary to the chimeric sequence 
of the adaptor plus the consensus Alu sequence after 
HpaII digestion (AACC + synthetic adaptor) and another 
one complementary to the Alu consensus sequence and 
located ~20 nucleotides upstream of the HpaII cutting 
site (Supplementary Figure S1). Thereby, qPCR of 
MspI digestion (qAlu M) allowed the quantification 
of all the amplifiable Alu elements (irrespective of the 
methylation status), while qPCR of HpaII digestion 
(qAlu H) only quantified the subset of amplifiable Alu 
elements containing an unmethylated CpG. Thus, the 
final result corresponded to the fraction of unmethylated 
Alu elements respect the total number of amplifiable Alu 
elements calculated according to the equation described 
below. Furthermore, two specific qPCRs for L1PA (a Long 
Interspersed Nuclear Element-1, LINE-1 subfamily) were 
performed to normalize the DNA input for both MspI 
(qL1PA M) and HpaII digestions (qL1PA H). For more 
technical details see Supplementary Material.
QUAlu data analysis
Statistical analyses were performed using R version 
3.1.0. The Percentage of UnMethylated Alu elements 
(PUMA) for each sample was assigned according to this 
equation:
The relative amount of unmethylated Alu elements 
(given by qAlu H normalized by the reference sequence 
qL1PA (qL1PA H)) and the relative amount of total 
amplifiable Alu elements (given by qAlu M normalized 
by qL1PA M) were calculated as a ratio of exponential 
functions in which the base was the qPCR efficiency (E) 
and the variable was the quantification cycle (Cq). To 
tackle the qPCR error propagation, permutation tests were 
done to obtain a final PUMA and its variation using the 
qPCR R package (v1.4-0, [41]). Mann-Whitney U test and 
Kruskal Wallis tests were used, as appropriate, to assess 
the significance among the different groups of samples. 
Correlation analyses were conducted using two-tailed 
Kendall tests. The significance level was established at 
p<0.05 for all analyses. Receiver operating characteristic 
(ROC) curves were generated using the pROC R package 
(v1.7.3, [42]) to assess the cut-off value that best 
discriminated between tumor and normal tissue according 
to the PUMA. 
Characterization of QUAlu product by Next 
Generation Sequencing
To determine the specificity of the technique, 
the products generated by qAlu H and qAlu M from 5 
samples (the colorectal cancer cell line HCT116, a lung 
squamous carcinoma with its normal matching tissue and 
a papillary thyroid carcinoma with its normal matching 
tissue) were sequenced using Ion Torrent technology 
(Life Technologies). For more technical details see 
Supplementary Material and Supplementary Table S3.
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